Innovstone Therapeutics discloses new cathepsin C inhibitors
AI Briefing
- • Innovstone Therapeutics discloses new cathepsin C inhibitors with potential for treating autoimmune diseases and cancer.
- • The inhibitors were synthesized to target dipeptidyl peptidase I (DPP-1) enzyme.
- • The new inhibitors show promise for treating autoimmune diseases and cancer.
Source Summary
Innovstone Therapeutics Ltd. has synthesized cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors found to be potentially useful for the treatment of autoimmune diseases and cancer.
Advertisement